• A Le Bris-Tomczak, J-P Bedos, C Billon, F Samdjee, and A Le Monnier.
• Service de pharmacie, centre hospitalier de Versailles, 177, rue de Versailles, 78150 Le Chesnay, France. aurelie.tomczak@gmail.com
• Med Mal Infect. 2012 May 1; 42 (5): 226-34.

ObjectiveThe authors had for aim to make an inventory of antibiotic treatment for severe community-acquired Streptococcus pneumoniae pneumonia and compare local practices to the local and national guidelines.Patients And MethodAn audit was conducted retrospectively in the Versailles hospital ICU between January 2006 and April 2009. Forty patients were included.ResultsNinety-three percent had major risk factors for pneumonia. Ninety-eight percent were treated, with the usual empirical treatment (69%) or treatment active against Pseudomonas aeruginosa (31%). Eighty-five percent of empirical treatment complied with the French national guidelines issued by the SPILF and 49% with the local ICU protocol, more restrictive for the choice of the agent and dose. Early de-escalation to amoxicillin was applied to 41% of patients after obtaining results for pneumococcal and Legionella antigen and results of respiratory sample direct examination. For all patients, empirical treatment was reassessed according to culture results: 81% were prescribed amoxicillin. Evaluation showed that 92% of treatment complied with SPILF guidelines and 65% with the local ICU protocol that required adaptation of amoxicillin doses according to MICs; adaptation to severity and BMI was necessary for ten patients. Mortality remained high, at 37%, despite using antibiotics still effective against S. pneumoniae.ConclusionsThis survey revealed a satisfactory adhesion to recommendations and prompt responsiveness of the team for adjustment of antibiotic therapy. The audit allowed updating the local ICU protocol.Copyright © 2012 Elsevier Masson SAS. All rights reserved.

38 keywords...

hide…